Tokyo, Aug. 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062680) titled 'Evaluation of the safety of intake of a nutraceutical containing highly concentrated S-1-propenyl-L-cysteine (S1PC) extract powder and NMN' on Aug. 25.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Tokyo Midtown Clinic Midtown Clinic Medical Corporation

Condition: Condition - Healthy individuals Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To evaluate the safety of intake of the product containing a high concentration of S1PC (20 mg) plus NMN (product name:IMAI-S1) through medical examinations, hematological tests, and blood biochemical tests conducted before, during, and after intake. To evaluate efficacy by assessing sleep, overall physical condition, and the condition of skin and hair before, during, and after intake, as well as by analyzing plasma and blood cell components, including the concentrations of nicotinamide adenine dinucleotide synthesis-related components in blood cells and plasma, and related activity, such as eNAMPT levels before and after the intake. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Intake of IMAI-S1 (S1PC 20mg and NMN 250mg) for 30 days

Eligibility: Age-lower limit - 40 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1. Individuals who have received a full explanation of the purpose and contents of this study, have the capacity to provide consent, have sufficiently understood the explanation, voluntarily wish to participate of their own free will, and have provided written consent to participate.

2. Adult men and women who are aged 40 years or older at the time consent is obtained. Key exclusion criteria - 1. Individuals who have regularly consumed pharmaceuticals or health related products containing nicotinamide adenine dinucleotide intermediate metabolites such as vitamin complexes or nicotinamide mononucleotide or NMN within the past two weeks. 2. Individuals with or suspected of having severe gastrointestinal, hepatic, renal, cardiovascular, hematological, or endocrine disorders, or malignant neoplasms, or a history thereof. 3. Individuals who are breastfeeding or pregnant, or who plan or wish to become pregnant during the study period. 4. Individuals currently taking anticoagulant medication. 5. Individuals with a history of severe allergy to the raw material of the test ingredient (garlic). 6. Individuals otherwise deemed unsuitable for the study by the principal investigator or study collaborators. Target Size - 30

Recruitment Status: Recruitment status - Enrolling by invitation Date of protocol fixation - 2026 Year 07 Month 08 Day Date of IRB - 2026 Year 07 Month 14 Day Anticipated trial start date - 2026 Year 08 Month 06 Day Last follow-up date - 2026 Year 10 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071675

Disclaimer: Curated by HT Syndication.